Pulling SEC filings + quote and writing the call…

CG Oncology, Inc.
Next earnings Aug 6, 2026 · consensus $-0.68 EPS, $341K rev
Last earnings +0.6% on 2026-05-08
Single-asset bladder-cancer biotech with a 2026 FDA decision pending — high-reward but binary, pre-revenue and not investable on fundamentals.
CG Oncology is a late-stage clinical biopharma whose entire value rests on one asset: cretostimogene, an oncolytic immunotherapy for non-muscle invasive bladder cancer (NMIBC). The science is genuinely promising — the 10-K reports 'potentially best-in-disease' Phase 3 data in BCG-unresponsive NMIBC, FDA Fast Track and Breakthrough Therapy designations, and a BLA initiated in Q4 2025 and expected to complete in 2026, addressing a market the company estimates at up to 150,000 patients across indications. A bladder-sparing alternative to radical cystectomy is a meaningful unmet need.
Sources: SEC EDGAR (CIK 0001991792, latest 10-Q filed 2026-05-08) · EODHD · analysis by claude-code · as of 6/21/2026, 8:57:25 PM.
Research and education only — not financial advice. EDGAR is not a registered investment adviser or broker-dealer and gives no personalized advice. Every call is impersonal — identical for all users, generated on a schedule from SEC filings plus a delayed/third-party price feed — may be wrong or out of date, and is not a recommendation to buy or sell any security. The operator and an affiliated trading operation may hold or trade the securities EDGAR rates; see Disclosures. Past performance does not guarantee future results. Do your own research.
The risks, catalysts, 12-month price target and the cited SEC figures behind this rating — with Pro.
Unlock with Pro€15/mo · cancel anytime
| Line item | FY23 | FY24 | FY25 |
|---|---|---|---|
| Revenue | $204K | $1.14M | $4.04M |
| Gross profit | — | — | — |
| Operating income | -$55.4M | -$115M | -$191M |
| Net income | -$48.6M | -$88.0M | -$161M |
| Diluted EPS | -$15.65 | -$1.41 | -$2.08 |
| Net margin | -23827.0% | -7729.5% | -3985.0% |
Annual figures from SEC 10-K XBRL filings. Open the filing links below for full statement detail.
Computed from SEC XBRL annual figures + the current quote. EV and ROIC use long-term + current debt where filed; estimates, not investment advice.
1074 tracked peers · median
Recent news tone vs the market's typical (which skews positive). A soft signal, not a recommendation.
Dates from 8-K (Item 2.02); beat/miss = reported EPS vs consensus (Finnhub, recent quarters); move = prior close → close on/after.
Last 90 days: 0 open-market buys · 4 sales
| 2026-06-22 | POST LEONARD E Director | Exercise | 5.00K @ $0.60 | $3.00K |
| 2026-06-22 | POST LEONARD E Director | Sell | 5.00K @ $65.00 | $325K |
| 2026-06-15 | Mulay James Director | Exercise | 654.00 @ $3.72 | $2.43K |
| 2026-06-15 | Mulay James Director | Sell | 654.00 @ $60.12 | $39.3K |
| 2026-06-15 | Mulay James Director | Exercise | 1.31K @ $12.59 | $16.5K |
| 2026-06-15 | Mulay James Director | Sell | 1.31K @ $60.12 | $78.8K |
| 2026-06-04 | POST LEONARD E Director | Exercise | 1.00K @ $0.60 | $600.00 |
| 2026-06-04 | POST LEONARD E Director | Sell | 1.00K @ $54.50 | $54.5K |